DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Business Affairs Homepage

Wendy Siminski AdvaMed welcomes senior vice president for conferences and events

Retail holds key to understanding digital expectations for healthcare Bringing simple and reliable digital interactions to the patient experience

CIVCO Radiotherapy and Adaptiiv ink distribution deal Partnership will increase access to software that personalizes radiotherapy

BWXT to acquire Sotera Health’s Nordion medical isotope business $150M in capital expenditures expected this year

With NVIDIA, Canon brings deep learning to its VNA Combining Abierto VNA data with DGX analytics

Four ways to attract prospective patients online Helping care seekers get from Google to your facility

Physicians should be granted immunity to malpractice lawsuits, says study Recorded a 13 percent decline in adverse events over four years

Fujifilm enters the US minimally-invasive surgery market Its new Boston-based business launched new products

FDA okays AI-driven device to identify diabetic retinopathy 'A historic moment' toward the future of healthcare

Study finds majority of U.S. radiologists practice as generalists Bringing new clarity to the composition of the imaging workforce

Abbott, Alere deal amended, could close third quarter 2017

by Thomas Dworetzky , Contributing Reporter
Abbott and Alere have agreed to amend their acquisition deal.

“Under the amended terms, Abbott will pay $51 per common share to acquire Alere, for a new expected equity value of approximately $5.3 billion, reduced from the originally expected equity value of approximately $5.8 billion,” the companies said in a statement.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



The deal is slated to close by the end of 2017's third quarter., subject to Alere shareholder approval and the usual regulatory and closing conditions.

The change in the deal includes moving the date for regulatory approvals from April 30 to September 30.

The transaction was announced on Feb. 1, 2016. "The combination of Alere and Abbott will create the world's premier point-of-care testing business and significantly strengthen and grow Abbott's diagnostics presence," said Miles D. White, chairman and chief executive officer of Abbott at the time. "We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that."

Alere was looking forward to the deal as well. "Today's announcement marks an exciting and transformative milestone for Alere and one that provides an immediate benefit for our stockholders," Namal Nawana, president and chief executive officer of Alere, noted at the time. "Our leading platforms and global presence in point-of-care diagnostics, combined with Abbott's broad portfolio of market-leading products, will accelerate our shared goal of improving patient care."

But the deal got rocky, with Abbott seeking to terminate it, even as late as December, 2016. "Alere is no longer the company Abbott agreed to buy 10 months ago," Abbott's Scott Stoffel, divisional vice president of external communications, explained at that point.

In the months following the February 1, 2016, announcement of the deal, stated Abbott, “Alere has suffered a series of damaging business developments, including the government eliminating the billing privileges of a substantial Alere division, the permanent recall of an important product platform, multiple new government subpoenas, including two new criminal subpoenas, and a five-month delay in filing its 10K, coupled with admissions of internal control failures requiring restatement of its 2013-2015 financials.”

Alere was hit with a pair of legal entanglements – a "foreign corruption investigation" subpoena over alleged payments in Asia, Africa, and Latin America, and a "government billing practices" investigation by the feds of its toxicology unit, over alleged inducements to doctors, according to Seeking Alpha.

Stoffel said that so many “negative developments” were “unprecedented and are not isolated incidents brought on by chance,” adding that, “this damage to Alere's business can only be the result of a systemic failure of internal controls, which, combined with the lack of transparency, led us to filing this complaint."

This came after Alere took Abbott to court as the deal soured. “Alere will take all actions necessary to protect the interests of Alere shareholders, enforce Alere’s rights under the merger agreement, and compel Abbott to complete the transaction in accordance with its terms,” according to a company statement in August, 2016.

That testing segment is worth about $5.5 billion annually and is “one of the fastest growing in vitro diagnostics segments,” stated the companies.

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED